Alexis Desieno Sells 24,778 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 24,778 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.40, for a total transaction of $84,245.20. Following the transaction, the chief financial officer now owns 140,948 shares in the company, valued at approximately $479,223.20. This represents a 14.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Alexis Desieno also recently made the following trade(s):

• On Friday, January 3rd, Alexis Desieno sold 8,854 shares of Cardlytics stock. The shares were sold at an average price of $3.67, for a total value of $32,494.18.

Cardlytics Stock Down 5.3 %

Shares of CDLX traded down $0.19 during trading hours on Tuesday, hitting $3.37. 810,748 shares of the company were exchanged, compared to its average volume of 895,995. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The company has a market cap of $171.26 million, a PE ratio of -0.55 and a beta of 1.54. The firm’s 50 day moving average is $3.47 and its 200-day moving average is $3.73. Cardlytics, Inc. has a 52 week low of $2.76 and a 52 week high of $20.52.

Institutional Investors Weigh In On Cardlytics

A number of large investors have recently added to or reduced their stakes in CDLX. Mirabella Financial Services LLP acquired a new position in Cardlytics in the 4th quarter valued at $4,285,000. D. E. Shaw & Co. Inc. boosted its holdings in Cardlytics by 97.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,131,505 shares of the company’s stock valued at $4,198,000 after acquiring an additional 558,235 shares during the period. RBF Capital LLC grew its position in shares of Cardlytics by 311.9% in the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares during the last quarter. GSA Capital Partners LLP increased its stake in shares of Cardlytics by 1,273.2% in the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after purchasing an additional 354,474 shares during the period. Finally, Rangeley Capital LLC bought a new position in shares of Cardlytics in the fourth quarter worth about $1,187,000. Institutional investors own 68.10% of the company’s stock.

Wall Street Analyst Weigh In

CDLX has been the subject of a number of recent research reports. Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a report on Friday, January 17th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Cardlytics currently has an average rating of “Hold” and an average price target of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.